Vandetanib

Generic Name
Vandetanib
Brand Names
Caprelsa
Drug Type
Small Molecule
Chemical Formula
C22H24BrFN4O2
CAS Number
443913-73-3
Unique Ingredient Identifier
YO460OQ37K
Background

Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.

On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.

Indication

Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.

Associated Conditions
Metastatic Thyroid Gland Medullary Carcinoma, Locally advanced Medullary thyroid cancer
Associated Therapies
-

A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

First Posted Date
2021-02-18
Last Posted Date
2024-01-05
Lead Sponsor
Hoffmann-La Roche
Registration Number
NCT04760288
Locations
🇪🇸

Hospital Universitario Virgen del Rocio, Sevilla, Spain

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2019-12-26
Last Posted Date
2024-06-13
Lead Sponsor
Loxo Oncology, Inc.
Target Recruit Count
291
Registration Number
NCT04211337
Locations
🇺🇸

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States

🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

🇺🇸

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 138 locations

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

First Posted Date
2018-08-14
Last Posted Date
2021-07-14
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
6
Registration Number
NCT03630120
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer

Phase 2
Conditions
Interventions
First Posted Date
2015-08-21
Last Posted Date
2015-08-21
Lead Sponsor
Velindre NHS Trust
Target Recruit Count
160
Registration Number
NCT02530411
Locations
🇬🇧

Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom

🇬🇧

Velindre Cancer Center, Velindre Hospital, Cardiff, Wales, United Kingdom

🇬🇧

Royal United Hospital Bath, Bath, United Kingdom

and more 2 locations

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

First Posted Date
2015-07-13
Last Posted Date
2021-01-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
7
Registration Number
NCT02495103
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

First Posted Date
2014-11-24
Last Posted Date
2024-01-10
Lead Sponsor
UNICANCER
Target Recruit Count
1460
Registration Number
NCT02299999
Locations
🇫🇷

Hopitaux Universitaire de Strasbourg - Hopital Civil, Strasbourg, France

🇫🇷

Institut Claudius Regaud, Toulouse, France

🇫🇷

Hopitaux Du Leman, Thonon-les-Bains, France

and more 21 locations

HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)

First Posted Date
2014-09-15
Last Posted Date
2020-10-08
Lead Sponsor
Amsterdam UMC, location VUmc
Target Recruit Count
15
Registration Number
NCT02239952
Locations
🇳🇱

VU University Medical Center, Amsterdam, Noord-Holland, Netherlands

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

First Posted Date
2014-04-17
Last Posted Date
2024-01-10
Lead Sponsor
UNICANCER
Target Recruit Count
999
Registration Number
NCT02117167
Locations
🇫🇷

Hôpital Avicenne, Bobigny, France

🇫🇷

Institut Bergonié, Bordeaux, France

🇫🇷

Institut Paoli Calmettes, Marseille, France

and more 34 locations
© Copyright 2024. All Rights Reserved by MedPath